Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Royalty income	$ 2,562	$ 3,319	$ 7,282	$ 7,888
License revenue	129	50,523	491	56,839
Other revenue	6	8	36	50
Total revenue	2,697	53,850	7,809	64,777
Operating expenses:
Research and development	10,344	9,827	31,641	26,964
General and administrative	5,958	7,220	17,986	18,637
Change in contingent consideration liability	700	600	3,300	1,400
Total operating expenses	17,002	17,647	52,927	47,001
Operating (loss) income	(14,305)	36,203	(45,118)	17,776
Other (expense) income:
Interest (expense) income, net	(1,047)	79	(3,230)	176
Total other (expense) income	(1,047)	79	(3,230)	176
Net (loss) income	(15,352)	36,282	(48,348)	17,952
Net loss attributable to noncontrolling interests		(21)		(58)
Net (loss) income attributable to Progenics	$ (15,352)	$ 36,303	$ (48,348)	$ 18,010
Net (loss) income per share attributable to Progenics - basic (in dollars per share)	$ (0.22)	$ 0.52	$ (0.69)	$ 0.26
Weighted-average shares - basic (in shares)	70,270	70,013	70,233	69,970
Net(loss) income per share attributable to Progenics - diluted (in dollars per share)	$ (0.22)	$ 0.52	$ (0.69)	$ 0.26
Weighted-average shares - diluted (in shares)	70,270	70,297	70,233	70,006